ClinicalTrials.gg
Enrolling by invitationNCT06086379CCT-COVIDUpdated Jul 15, 2026

Cognitive Rehabilitation Therapy for COVID-19

An interventional study of Compensatory Cognitive Training for COVID-19 and Holistic Cognitive Education in Post-Acute COVID-19 Syndrome, sponsored by VA Office of Research and Development. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development — 8 open to participants now, 8 under way, none of them phase 3. Post-Acute COVID-19 Syndrome · VA Office of Research and Development.

Started
2024
with 2 others
No phase
7 of 11
5 open now
Registered
7th of 11
by date

Among the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development, this one is one of 3 that started in 2024, is one of 7 with no phase, and was the 7th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

8 of the 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Post-Acute COVID-19 Syndrome by VA Office of Research and Development, or all of them as a file.
02

Study summary

Cognitive dysfunction, psychiatric symptoms, functional impairment, and disability following COVID-19 negatively impact Veterans' community functioning and quality of life, contribute to significant human suffering, and are costly to VHA. Rehabilitation is a critical priority for Veterans with long COVID. One promising treatment to improve functioning in Veterans with post-COVID-19 cognitive symptoms is Compensatory Cognitive Training (CCT). Previous studies have found that CCT is feasible, acceptable, and efficacious in Veteran populations with multiple sources of cognitive dysfunction. This randomized controlled trial aims to address important RR\&D priorities by examining feasibility, acceptability, and preliminary efficacy of a COVID-19-specific rehabilitation intervention, CCT for long COVID (CCT-C) compared to a robust control condition. The proposed study has the potential to improve cognitive function, functional independence, and quality of life for Veterans with late or delayed effects of secondary conditions related to COVID-19 infections.

Read the detailed description

2-8% of the US population report "long COVID" symptoms - including "brain fog," thinking difficulties, memory problems, and psychiatric symptoms such as sleep disturbance, anxiety, and depression. Rates of post-COVID-19 symptoms are nearly double in the Veteran population. These cognitive symptoms contribute to functional impairments, reduced quality of life, poorer self-reported health status, psychological distress, delayed return to work, new onset disability, reduced community integration, and increased healthcare utilization. One promising treatment to improve both everyday functioning and cognition secondary to post-COVID-19 symptoms is Compensatory Cognitive Training (CCT). Previous studies have found that CCT is feasible, acceptable, and efficacious in Veteran populations with multiple sources of cognitive dysfunction. The proposed CDA provides a golden opportunity to evaluate CCT for Veterans with prolonged COVID-19 symptoms (CCT-C), compared with a robust control condition, Holistic Cognitive Education (HCE). The project closely aligns with current RR\&D priorities, by "examining COVID-19-specific rehabilitation interventions and responses to treatment" and by addressing "late or delayed effects of secondary conditions related to COVID-19 infections on impairment and disability." Specific aims are 1) to conduct a pilot randomized controlled trial of remote CCT-C with 70 Veterans (35 CCT-C, 35 HCE) with post-COVID-19 cognitive symptoms to examine feasibility, acceptability, and initial efficacy; 2) to examine the preliminary efficacy of CCT-C in this population on overall functioning, as measured by the World Health Organization's Disability Assessment Schedule (WHODAS 2.0), performance-based measures of functional capacity, and secondary outcomes (cognitive performance, quality of life, self-reported cognitive problems, psychiatric symptoms, sleep disturbance, and engagement in work/community activities); and 3) to explore moderators of outcome (e.g., age, initial COVID-19 severity, baseline cognitive functioning, presence of PTSD/mTBI history; biomarkers related to COVID-19 infection).

03

Conditions studied

  • Post-Acute COVID-19 Syndrome

Keywords

  • Post-Acute COVID-19 Syndrome
  • Cognitive rehabilitation
  • Cognitive training
  • Cognitive remediation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Veterans > 18 years old who are able to provide
  • Prior participation in SF Parent Study or LA Parent Study
  • Report of cognitive symptoms that Veteran attributes to COVID-19 infection

Exclusion criteria

Exclusion Criteria:

  • Current substance abuse disorder, psychotic disorder, dementia, etc.
  • History of moderate to severe brain injury with loss of consciousness > 30 minutes
  • Auditory or visual impairments that would prevent the ability to participate in assessment procedures
  • Invalid performance on one or more embedded performance validity tests (PVTs)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    CCT-C

    10-week Compensatory Cognitive Training Group

    Behavioral: Compensatory Cognitive Training for COVID-19

  • Active comparator
    HCE

    10-week Holistic Cognitive Education Group

    Behavioral: Holistic Cognitive Education

Interventions

  • BehavioralCompensatory Cognitive Training for COVID-19

    CCT-C is a manualized group-based behavioral intervention (10 weeks, 2 hours per week, 20 hours total) designed to improve cognition and everyday functioning in patients with prolonged COVID-19 symptoms

    Also known as: CCT-C

  • BehavioralHolistic Cognitive Education

    HCE provides the same frequency and amount of therapist and other group member contact as CCT-C, but does not provide training in cognitive or lifestyle strategies addressed in CCT-C. The HCE intervention provides information and discussion regarding common causes of and treatments for cognitive impairment.

    Also known as: HCE

06

What researchers measure

Primary outcomes

  1. Change in World Health Organization - Disability Assessment Schedule (WHODAS 2.0)

    Change in average total score

    Time frame: baseline, 8 weeks

Secondary outcomes

  1. Change in objective cognitive performance z score

    Change in composite z score

    Time frame: baseline, 8 weeks

  2. Change in functional capacity performance z score

    Change in composite z score

    Time frame: baseline, 8 weeks

  3. Change in Patient Health Questionnaire 9 (PHQ-9)

    Change in total score

    Time frame: baseline, 8 weeks

  4. Change in Generalized Anxiety Disorder 7 (GAD-7)

    Change in total score

    Time frame: baseline, 8 weeks

  5. Change in PTSD Checklist for DSM-5 (PCL-5)

    Change in total score

    Time frame: baseline, 8 weeks

  6. Change in Cognitive Failures Questionnaire (CFQ)

    Change in total score

    Time frame: baseline, 8 weeks

  7. Change in Neuro-QOL: Applied Cognition General Concerns

    Change in total score

    Time frame: baseline, 8 weeks

  8. Change in Neuro-QOL: Applied Cognition Executive Functioning

    Change in total score

    Time frame: baseline, 8 weeks

  9. Change in Neuro-QOL: Fatigue

    Change in total score

    Time frame: baseline, 8 weeks

  10. Change in World Health Organization - Quality of Life (WHOQOL-BREF)

    Change in total score

    Time frame: baseline, 8 weeks

  11. Change in Insomnia Severity Index (ISI)

    Change in total score

    Time frame: baseline, 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2027, 35 months after the start.

Of 232 non-industry interventional studies with no phase under Post-Acute COVID-19 Syndrome, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 35 months is above that.

Counting every sponsor, half of 243 studies reached it within 16 months; a quarter within 7 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Oct 17, 2023
StartActual
Jul 1, 2024
Primary completionEst.
Jun 30, 2027
CompletionEst.
Mar 31, 2029
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06086379
Responsible party
Sponsor
First posted
Oct 17, 2023
Start date
Jul 1, 2024
Primary completion
Jun 30, 2027 (estimated)
Completion
Mar 31, 2029 (estimated)
Last update
Jul 15, 2026

Study contacts

Tara A Austin, AA
principal investigator · VA San Diego Healthcare System, San Diego, CA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion